D-1229-2020 Class II Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-1229-2020 was initiated by Aurobindo Pharma USA Inc. on March 18, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed The recall status is terminated (terminated March 25, 2024). Affected quantity: 14194 units.

Recall Details

Product Type
Drugs
Report Date
April 22, 2020
Initiation Date
March 18, 2020
Termination Date
March 25, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
14194 units

Product Description

Acetaminophen and Codeine Phosphate Tablets, USP, 300 mg/15 mg, 100-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ 08810, NDC 13107-058-01

Reason for Recall

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

Distribution Pattern

Nationwide within the United States

Code Information

Lot #: 058180015A, 058180016A, Exp. Date 07/2021; 05818017B1, Exp. Date 09/2021